{
    "clinical_study": {
        "@rank": "45396", 
        "arm_group": [
            {
                "arm_group_label": "Simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Arm 1: Simvastatin 40mg / pill, one pill once a day for  three months"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Arm 2: Placebo one pill once a day for three months"
            }
        ], 
        "brief_summary": {
            "textblock": "It\u00b4s a clinical research of the effects in portal hypertension caused by simvastatin. We are\n      going to use the hepatic venous pressure gradient(HVPG) measurement and the azygos flow at\n      echoendoscopy to evaluate the benefits of the drug. Preliminary studies demonstrated that\n      simvastatin can lower portal pressure."
        }, 
        "brief_title": "Simvastatin Effect on Portal Hypertension", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Portal Hypertension", 
            "Esophageal Varices", 
            "Liver Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Esophageal and Gastric Varices", 
                "Hypertension", 
                "Hypertension, Portal", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Varicose Veins"
            ]
        }, 
        "detailed_description": {
            "textblock": "The simvastatin can target the liver enhancing nitric oxide intra-hepatic and lowering\n      resistance that may be responsible for most of cirrhosis complications. Indeed, the\n      potential use of this drug may ameliorate the HVPG and azygos flow. Portal hypertension is\n      responsible for most of the cases of death in cirrhosis. The esophageal varices, ascites and\n      hepatorenal syndrome are the most harmful consequences of cirrhosis that should be\n      prevented. In that way, simvastatin appears as a promising therapy.The study will include\n      two groups of patients using aleatory randomization and one group will receive simvastatin\n      while the other will receive placebo blindly. At the start and at the end of the study the\n      patients will be submitted to HVPG measurement and azygous vein flow measure.\n\n      The endpoints will be the normalization of HVPG or lower significantly(20% or more.\n\n      The patients will be followed for 6 months after the end of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Portal hypertension: esophageal varices, ascites, splenomegaly or hepatorenal\n             syndrome.\n\n        Exclusion Criteria:\n\n          -  Child-Pugh C decompensated or encephalopathy\n\n          -  Malignancy except basocellular cancer\n\n          -  Hepatocarcinoma\n\n          -  Anti-viral therapy\n\n          -  HIV\n\n          -  Prevention of digestive hemorrhage with band ligation or sclerotherapy for the last 6\n             months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134626", 
            "org_study_id": "simvhp01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Simvastatin", 
                "description": "40mg / pill, one pill orally once a day for three months", 
                "intervention_name": "Simvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "intervention_name": "Placebo pill", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Portal Hypertension", 
            "Hepatic Venous Pressure Gradient", 
            "Esophageal Varices", 
            "Liver Cirrhosis", 
            "Simvastatin", 
            "Nitric oxide", 
            "HVPG"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rio de Janeiro", 
                    "country": "Brazil"
                }, 
                "name": "Federal University of Rio de Janeiro"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy", 
        "overall_official": {
            "affiliation": "Federal University of Rio de Janeiro - UFRJ", 
            "last_name": "Priscila Pollo-Flores, MD, Master", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Positive results consist of reduction of the HVPG to values equal or less than 12 mmHg or 20% lower than the first measure", 
            "measure": "Hepatic venous pressure gradient (HVPG) in mmHg units", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134626"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidade Federal do Rio de Janeiro", 
            "investigator_full_name": "Guilherme Rezende", 
            "investigator_title": "Associate Professor of the Medical Faculty", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universidade Federal do Rio de Janeiro", 
        "sponsors": {
            "collaborator": {
                "agency": "Rio de Janeiro State Research Supporting Foundation (FAPERJ)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Universidade Federal do Rio de Janeiro", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}